Has brigatinib been included in medical insurance? What are the conditions and proportions of medical insurance reimbursement?

Brigatinib (Brigatinib) is a targeted drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). It is suitable for patients with disease progression or intolerance after previous treatment with crizotinib (Crizotinib). Currently, the drug has been launched in China and has been successfully included in medical insurance, allowing patients to obtain treatment at a relatively low price.

With the coverage of medical insurance, the price of brigatinib has dropped significantly. The current domestic purchase price is about four to five thousand yuan. However, the specific reimbursement ratio and conditions of medical insurance may vary from region to region. Generally speaking, patients need to meet the standards for medical insurance reimbursement, such as being diagnosed with ALK-positive advanced or metastatic non-small cell lung cancer and receiving a prescription from a doctor before they can enjoy medical insurance reimbursement. The specific reimbursement ratio is usually between 60%-80%, but patients are advised to consult their local hospital or medical insurance agency for the latest policy.

Compared with domestic ones, the price of generic drugs of brigatinib in foreign markets is lower, especially those in Laos and other places, which cost about several hundred yuan per box, which is much lower than the domestic original drug. Although the ingredients of these generic drugs are basically the same, due to differences in production standards, regulatory systems and approval processes, patients should be cautious when choosing, and it is best to decide whether to use generic drugs under the guidance of a doctor.

In general, brigatinib has significantly reduced the financial burden on patients after entering medical insurance, and provides a more accessible treatment option for patients with ALK positive lung cancer. For patients who need to purchase medicines, it is recommended to give priority to regular channels to purchase medicines covered by medical insurance, and pay close attention to the updates of medical insurance policies to ensure the best treatment options and financial support.

Reference materials:https://www.alunbrig.com/